Aquestive, a specialty pharmaceutical company, outperformed the S&P 500 gain this year.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aquestive, a specialty pharmaceutical company, outperformed the S&P 500 gain this year.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Aquestive, a specialty pharmaceutical company, seeks international regulatory approval in Canada.Sub-event
Aquestive (specialty pharma) outperformed S&P 500 gains this year.1 source
Aquestive stock underperformed the S&P 500 in August 2025.1 source
Keep exploring
The entities involved
-
Aquestive (United States)
company in Warren Township, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksAquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of
- ZacksCompared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics Aquestive Therapeutics (AQST) reported $10 million in revenue for the quarter ended June 2025, representing a y